Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial. - Mell, Loren K; Torres-Saavedra, Pedro A; Wong, Stuart J; Kish, Julie A; Chang, Steven S; Jordan, Richard C; Liu, Tian; Truong, Minh Tam; Winquist, Eric W; Takiar, Vinita; Wise-Draper, Trisha; Robbins, Jared R; et al. (Lancet Oncology, 2024)